Compare
Ultragenyx Pharmaceutical Inc. vs Kiniksa Pharmaceuticals International, plc vs Pacira BioSciences, Inc. vs TG Therapeutics, Inc.
| Latest fiscal year | Ultragenyx Pharmaceutical Inc. RARE | Kiniksa Pharmaceuticals International, plc KNSA | Pacira BioSciences, Inc. PCRX | TG Therapeutics, Inc. TGTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $673.00M | $677.56M | $726.41M | $616.29M |
| Revenue growth (YoY) | +20.2% | +60.1% | +3.6% | +87.3% |
| Gross margin | n/a | 88.5% (computed) | 79.4% (computed) | 83.7% (computed) |
| Operating margin | -79.5% | 11.4% | 2.6% | 20.0% |
| Net margin | -85.4% | 8.7% | 1.0% | 72.6% |
| Net income | -$575.00M | $59.01M | $7.03M | $447.18M |
| EPS (Diluted) | -$5.83 | $0.75 | $0.16 | $2.77 |
| Operating cash flow | -$466.00M | $137.99M | $151.99M | -$24.77M |
| Free cash flow | -$472.00M | $136.42M | $136.66M | -$24.99M |
| Cash & equivalents | $421.00M | $165.60M | $158.54M | $79.15M |
| Total assets | $1.53B | $763.63M | $1.26B | $1.06B |
| Total liabilities | $1.60B | $196.03M | $571.81M | $415.23M |
| Shareholders' equity | -$80.00M | $567.61M | $693.11M | $648.02M |
| Return on year-end equity | n/a | 10.4% | 1.0% | 69.0% |
| Shares outstanding | 96.60M | n/a | 41.12M | 155.31M |
Revenue, most recent five fiscal years
| Fiscal year | Ultragenyx Pharmaceutical Inc. | Kiniksa Pharmaceuticals International, plc | Pacira BioSciences, Inc. | TG Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $673.00M Ended 2025-12-31 | $677.56M Ended 2025-12-31 | $726.41M Ended 2025-12-31 | $616.29M Ended 2025-12-31 |
| 1 year earlier | $560.00M Ended 2024-12-31 | $423.24M Ended 2024-12-31 | $700.97M Ended 2024-12-31 | $329.00M Ended 2024-12-31 |
| 2 years earlier | $434.00M Ended 2023-12-31 | $270.26M Ended 2023-12-31 | $674.98M Ended 2023-12-31 | $233.66M Ended 2023-12-31 |
| 3 years earlier | $363.33M Ended 2022-12-31 | $220.18M Ended 2022-12-31 | $666.82M Ended 2022-12-31 | $2.79M Ended 2022-12-31 |
| 4 years earlier | $351.41M Ended 2021-12-31 | $38.54M Ended 2021-12-31 | $541.53M Ended 2021-12-31 | $6.69M Ended 2021-12-31 |